SG11201605366QA - Pharmaceutical composition containing pyridylaminoacetic acidcompound - Google Patents
Pharmaceutical composition containing pyridylaminoacetic acidcompoundInfo
- Publication number
- SG11201605366QA SG11201605366QA SG11201605366QA SG11201605366QA SG11201605366QA SG 11201605366Q A SG11201605366Q A SG 11201605366QA SG 11201605366Q A SG11201605366Q A SG 11201605366QA SG 11201605366Q A SG11201605366Q A SG 11201605366QA SG 11201605366Q A SG11201605366Q A SG 11201605366QA
- Authority
- SG
- Singapore
- Prior art keywords
- acidcompound
- pharmaceutical composition
- composition containing
- pyridylaminoacetic
- containing pyridylaminoacetic
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014002810 | 2014-01-10 | ||
| PCT/JP2015/050334 WO2015105135A1 (en) | 2014-01-10 | 2015-01-08 | Pharmaceutical composition containing pyridylamino acetic acid compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201605366QA true SG11201605366QA (en) | 2016-08-30 |
Family
ID=53523960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201605366QA SG11201605366QA (en) | 2014-01-10 | 2015-01-08 | Pharmaceutical composition containing pyridylaminoacetic acidcompound |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10149908B2 (en) |
| EP (1) | EP3093019B1 (en) |
| JP (1) | JP6441087B2 (en) |
| KR (1) | KR102281620B1 (en) |
| CN (1) | CN105828818B (en) |
| AU (1) | AU2015205179B2 (en) |
| BR (1) | BR112016015909B1 (en) |
| CA (1) | CA2935055C (en) |
| EA (1) | EA031813B1 (en) |
| ES (1) | ES2875307T3 (en) |
| GE (1) | GEP20196982B (en) |
| IL (1) | IL246655B (en) |
| MX (2) | MX385505B (en) |
| MY (1) | MY179951A (en) |
| PH (1) | PH12016501328B1 (en) |
| SG (1) | SG11201605366QA (en) |
| TW (1) | TWI650127B (en) |
| UA (1) | UA121746C2 (en) |
| WO (1) | WO2015105135A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150279T1 (en) | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| EP3424503B1 (en) * | 2014-01-10 | 2020-09-02 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation including pyridylamino acetic acid compound |
| CA2934612C (en) * | 2014-01-10 | 2021-09-07 | Santen Pharmaceutical Co., Ltd. | Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition |
| BR112016015909B1 (en) | 2014-01-10 | 2020-09-29 | Santen Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND |
| JP7032134B2 (en) | 2015-07-09 | 2022-03-08 | 参天製薬株式会社 | Prophylactic and / or therapeutic agents containing pyridylaminoacetic acid compounds |
| US20190038598A1 (en) * | 2016-02-22 | 2019-02-07 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition including dorzolamide and brimonidine |
| WO2018230713A1 (en) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
| CA3067332A1 (en) | 2017-06-16 | 2018-12-20 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| JP7250685B2 (en) * | 2017-09-29 | 2023-04-03 | 参天製薬株式会社 | Medicine containing pyridylaminoacetic acid compound |
| WO2019124487A1 (en) | 2017-12-21 | 2019-06-27 | 参天製薬株式会社 | Omidenepag combination |
| EP3733179A4 (en) | 2017-12-28 | 2021-09-15 | Santen Pharmaceutical Co., Ltd. | PHARMACEUTICAL PREPARATION WITH A PYRIDYLAMINOACETIC ACID |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4960799A (en) * | 1988-09-13 | 1990-10-02 | Ciba-Geigy Corporation | Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use |
| US5631287A (en) | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| JP3297969B2 (en) | 1994-12-26 | 2002-07-02 | ライオン株式会社 | Eye drops |
| EP0938896A1 (en) * | 1998-01-15 | 1999-09-01 | Novartis AG | Autoclavable pharmaceutical compositions containing a chelating agent |
| ATE285795T1 (en) | 1998-07-14 | 2005-01-15 | Alcon Mfg Ltd | POLYPROPYLENE BASED CONTAINERS FOR PROSTAGLANDIN CONTAINING PRODUCTS |
| US6235781B1 (en) | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
| US20020009507A1 (en) | 2000-01-19 | 2002-01-24 | Alcon Universal Ltd. | Use of polyethoxylated castor oil for the treatment of dry eye |
| JP2002356420A (en) * | 2001-03-27 | 2002-12-13 | Santen Pharmaceut Co Ltd | Stable aqueous solution |
| JP5460996B2 (en) * | 2007-10-19 | 2014-04-02 | 大正製薬株式会社 | Ophthalmic agent |
| US8648097B2 (en) * | 2008-03-12 | 2014-02-11 | Ube Industries, Ltd. | Pyridylaminoacetic acid compound |
| ES2564010T3 (en) * | 2009-03-30 | 2016-03-17 | Ube Industries, Ltd. | Pharmaceutical composition to treat or prevent glaucoma |
| JP2011057633A (en) * | 2009-09-11 | 2011-03-24 | Ube Industries Ltd | Medicine containing pyridylaminoacetic acid compound |
| JP2012180346A (en) * | 2011-02-10 | 2012-09-20 | Santen Pharmaceut Co Ltd | Aqueous composition having improved drug migration property of hydrophilic drug |
| CA2830896A1 (en) | 2011-04-12 | 2012-10-18 | Yukihiko Mashima | Aqueous ophthalmic composition |
| CN104136019A (en) * | 2012-02-27 | 2014-11-05 | 日本乐敦制药株式会社 | Ophthalmic Composition Kit |
| ES2702575T3 (en) | 2012-03-26 | 2019-03-04 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol |
| WO2014010354A1 (en) | 2012-07-09 | 2014-01-16 | シャープ株式会社 | Light emission device, illumination device, and insulating substrate |
| CA3099517C (en) | 2012-07-13 | 2022-04-26 | Santen Pharmaceutical Co., Ltd. | Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension |
| US20140018350A1 (en) | 2012-07-13 | 2014-01-16 | Asahi Glass Co., Ltd. | Combination of sulfonamide compound and tafluprost |
| JP2014019650A (en) * | 2012-07-13 | 2014-02-03 | Santen Pharmaceut Co Ltd | Combination of sulfonamide compound and tafluprost |
| US9339496B2 (en) * | 2012-07-13 | 2016-05-17 | Santen Pharmaceutical Co., Ltd. | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist |
| BR112016015909B1 (en) | 2014-01-10 | 2020-09-29 | Santen Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND |
| CA2934612C (en) * | 2014-01-10 | 2021-09-07 | Santen Pharmaceutical Co., Ltd. | Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition |
| EP3424503B1 (en) * | 2014-01-10 | 2020-09-02 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation including pyridylamino acetic acid compound |
-
2015
- 2015-01-08 BR BR112016015909-8A patent/BR112016015909B1/en active IP Right Grant
- 2015-01-08 MX MX2020003133A patent/MX385505B/en unknown
- 2015-01-08 AU AU2015205179A patent/AU2015205179B2/en active Active
- 2015-01-08 ES ES15735316T patent/ES2875307T3/en active Active
- 2015-01-08 CN CN201580003108.9A patent/CN105828818B/en active Active
- 2015-01-08 TW TW104100528A patent/TWI650127B/en active
- 2015-01-08 KR KR1020167016405A patent/KR102281620B1/en active Active
- 2015-01-08 JP JP2015002272A patent/JP6441087B2/en active Active
- 2015-01-08 GE GEAP201514215A patent/GEP20196982B/en unknown
- 2015-01-08 SG SG11201605366QA patent/SG11201605366QA/en unknown
- 2015-01-08 MY MYPI2016001272A patent/MY179951A/en unknown
- 2015-01-08 EP EP15735316.0A patent/EP3093019B1/en active Active
- 2015-01-08 UA UAA201608085A patent/UA121746C2/en unknown
- 2015-01-08 CA CA2935055A patent/CA2935055C/en active Active
- 2015-01-08 MX MX2016009049A patent/MX2016009049A/en unknown
- 2015-01-08 WO PCT/JP2015/050334 patent/WO2015105135A1/en not_active Ceased
- 2015-01-08 EA EA201691244A patent/EA031813B1/en unknown
-
2016
- 2016-07-04 PH PH12016501328A patent/PH12016501328B1/en unknown
- 2016-07-07 US US15/204,507 patent/US10149908B2/en active Active
- 2016-07-07 IL IL246655A patent/IL246655B/en active IP Right Grant
-
2018
- 2018-10-29 US US16/173,299 patent/US10485872B2/en active Active
-
2019
- 2019-10-21 US US16/658,585 patent/US10765750B2/en active Active
-
2020
- 2020-07-30 US US16/942,877 patent/US20200353084A1/en not_active Abandoned
-
2023
- 2023-10-02 US US18/479,338 patent/US20240024484A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282481A (en) | Liquid pharmaceutical composition | |
| GB201618482D0 (en) | Pharmaceutical compositions | |
| GB201419257D0 (en) | Pharmaceutical compositions | |
| IL277241A (en) | Liquid pharmaceutical composition | |
| GB201409471D0 (en) | Pharmaceutical composition | |
| IL249553A0 (en) | Pharmaceutical compositions | |
| IL249117A0 (en) | Liquid pharmaceutical composition | |
| SG11201605366QA (en) | Pharmaceutical composition containing pyridylaminoacetic acidcompound | |
| GB201409488D0 (en) | Pharmaceutical composition | |
| GB201409485D0 (en) | Pharmaceutical composition | |
| LT3278801T (en) | Pharmaceutical composition containing mirabegron | |
| ZA201508726B (en) | Pharmaceutical composition | |
| ZA201502073B (en) | Pharmaceutical composition | |
| IL250817A0 (en) | Pharmaceutical compositions | |
| ZA201700278B (en) | Pharmaceutical composition containing docetaxel | |
| SMT202000391T1 (en) | Pharmaceutical composition | |
| SG10201504332VA (en) | Pharmaceutical Composition | |
| SG11201608123VA (en) | Pharmaceutical composition for external use | |
| SG11201608124XA (en) | Pharmaceutical composition for external use | |
| SG11201608122PA (en) | Pharmaceutical composition for external use | |
| SG2014014872A (en) | Pharmaceutical compositions | |
| GB201408432D0 (en) | Pharmaceutical compositions |